Advertisement

Radiation-induced glucocorticoid receptor promotes CD44+ prostate cancer stem cell growth through activation of SGK1-Wnt/β-catenin signaling

  • Feng Chen
  • Xiaodong Chen
  • Yu Ren
  • Guobin Weng
  • Peter C. Keng
  • Yuhchyau ChenEmail author
  • Soo Ok LeeEmail author
Original Article

Abstract

We observed cancer stem cell (CSC) population increase in radioresistant LNCaP (LNCaPR18) and C4-2 (C4-2R26) prostate cancer (PCa) cells compared with respective parental cells. Since the CD44 level increase was most significant in radioresistant PCa cells compared with parental cells among CSC markers tested, we isolated the CD44+ population from LNCaP/LNCaPR18 and C4-2/C4-2R26 cell sets via the immunomagnetic separation method and used them as CSC sources. We detected lower AR level, but higher glucocorticoid receptor (GR) level in CD44+ CSCs than CD44- non-CSCs. Higher GR level in CD44+ CSCs than CD44- cells was also detected when cells were isolated from mouse tumor tissues of LNCaPR18 cell and C4-2R26 cell–derived human xenografts and grown in culture. We then found blocking the GR signaling by adding the anti-GR agent mifepristone into the cell culture inhibited the CD44+ CSC growth while the addition of the anti-AR agent enzalutamide enhanced the CSC growth. In xenograft mouse studies in which tumors were developed from the injection of CD44+ CSCs of LNCaPR18 or C4-2R26 cell lines, retarded tumor growth in mifepristone-injected mice was observed compared with vehicle-treated mice. We next discovered the GR regulation of Wnt/β-catenin signaling pathway. We further found that the serum/glucocorticoid regulated kinase 1 (SGK1) is the GR downstream molecule that mediates Wnt/β-catenin signaling activation. Therefore, inhibition of either SGK1 or Wnt/β-catenin signaling impaired the in vitro CD44+ CSC growth. From these results, we suggest that blocking GR signaling or its downstream SGK1-Wnt/β-catenin signaling axis may suppress the radiation-induced CSC increase in PCa.

Key Messages

  • Higher CSC population exists in radioresistant PCa cells than parental cells.

  • Higher GR levels (and lower AR level) in CD44+ CSCs than CD44- non-CSCs.

  • Use of anti-GR agent blocked the growth of CD44+ CSCs in in vitro/in vivo tests.

  • GR downstream SGK1-Wnt/β-catenin signaling axis mediates the CSC increase.

  • Targeting this signaling axis may enhance the radiotherapy efficacy in treating PCa.

Keywords

Radioresistance GR Prostate cancer stem cells SGK1 Wnt/β-catenin 

Notes

Acknowledgments

We thank Mrs. Laura Finger for assistance with manuscript preparation.

Funding

This work was supported by the Richard T. Bell Endowed Professorship (YC).

Compliance with ethical standards

Ethics approval and consent to participate

All animal studies were performed under the supervision and guidelines of the University of Rochester Medical Center’s Animal Care and Use Committee. The facilities and programs for animal care at the University of Rochester comply with state and federal laws and NIH policies. The entire Animal Resource Program is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Human samples were not used in this study.

Conflict of interest

The authors declare that they have no conflicts of interest.

Supplementary material

109_2019_1807_MOESM1_ESM.docx (13 kb)
Supplementary Table 1 (DOCX 13 kb)
109_2019_1807_Fig7_ESM.png (369 kb)
Supplementary Figure 1

(PNG 369 kb)

109_2019_1807_MOESM2_ESM.tif (4.1 mb)
High resolution image (TIF 4221 kb)

References

  1. 1.
    Baumann M, Krause M, Hill R (2008) Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8:545–554CrossRefGoogle Scholar
  2. 2.
    Li F, Zhou K, Gao L, Zhang B, Li W, Yan W, Song X, Yu H, Wang S, Yu N, Jiang Q (2016) Radiation induces the generation of cancer stem cells: a novel mechanism for cancer radioresistance. Oncol Lett 12:3059–3065CrossRefGoogle Scholar
  3. 3.
    Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25:1696–1708CrossRefGoogle Scholar
  4. 4.
    Underwood W 3rd, Jackson J, Wei JT, Dunn R, Baker E, Demonner S, Wood DP (2005) Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer 103:538–545CrossRefGoogle Scholar
  5. 5.
    Vanneste BG, Van Limbergen EJ, van Lin EN, van Roermund JG, Lambin P (2016) Prostate cancer radiation therapy: what do clinicians have to know? Biomed Res Int 2016:6829875CrossRefGoogle Scholar
  6. 6.
    Bonkhoff H (2012) Factors implicated in radiation therapy failure and radiosensitization of prostate cancer. Prostate Cancer 2012:593241CrossRefGoogle Scholar
  7. 7.
    Gomez-Casal R, Bhattacharya C, Ganesh N, Bailey L, Basse P, Gibson M, Epperly M, Levina V (2013) Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol Cancer 12:94CrossRefGoogle Scholar
  8. 8.
    Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25:276–308CrossRefGoogle Scholar
  9. 9.
    Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee HJ, Wang C, Mizokami A (1995) Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr 5:97–125CrossRefGoogle Scholar
  10. 10.
    Li K, Guo Y, Yang X, Zhang Z, Zhang C, Xu Y (2017) ELF5-mediated AR activation regulates prostate cancer progression. Sci Rep 7:42759.  https://doi.org/10.1038/srep42759 CrossRefGoogle Scholar
  11. 11.
    Lai KP, Huang CK, Chang YJ, Chung CY, Yamashita S, Li L, Lee SO, Yeh S, Chang C (2013) New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol 182:460–473CrossRefGoogle Scholar
  12. 12.
    Morales A, Connolly JG, Bruce AW (1971) Androgen therapy in advanced carcinoma of the prostate. Can Med Assoc J 105:71–72Google Scholar
  13. 13.
    Imamura Y, Sadar MD (2016) Androgen receptor targeted therapies in castration-resistant prostate cancer: bench to clinic. Int J Urol 23:654–665CrossRefGoogle Scholar
  14. 14.
    Zhou J, Cidlowski JA (2005) The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 70:407–417CrossRefGoogle Scholar
  15. 15.
    Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT (2004) Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci U S A 101:4758–4763CrossRefGoogle Scholar
  16. 16.
    Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155:1309–1322CrossRefGoogle Scholar
  17. 17.
    Xie N, Cheng H, Lin D, Liu L, Yang O, Jia L, Fazli L, Gleave ME, Wang Y, Rennie P, Dong X (2015) The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer J Int du Cancer 136:E27–E38CrossRefGoogle Scholar
  18. 18.
    Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, Conzen SD, Szmulewitz RZ (2014) Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer 5:72–89CrossRefGoogle Scholar
  19. 19.
    Kroon J, Puhr M, Buijs JT, van der Horst G, Hemmer DM, Marijt KA, Hwang MS, Masood M, Grimm S, Storm G, Metselaar JM, Meijer OC, Culig Z, van der Pluijm G (2016) Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer. Endocr Relat Cancer 23:35–45CrossRefGoogle Scholar
  20. 20.
    Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315–2319CrossRefGoogle Scholar
  21. 21.
    Lee SO, Ma Z, Yeh CR, Luo J, Lin TH, Lai KP, Yamashita S, Liang L, Tian J, Li L, Jiang Q, Huang CK, Niu Y, Yeh S, Chang C (2013) New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell Biol 5:14–26CrossRefGoogle Scholar
  22. 22.
    Kach J, Long TM, Selman P, Tonsing-Carter EY, Bacalao MA, Lastra RR, de Wet L, Comiskey S, Gillard M, VanOpstall C, West DC, Chan WC, Griend DV, Conzen SD, Szmulewitz RZ (2017) Selective glucocorticoid receptor modulators (SGRMs) delay castrate-resistant prostate cancer growth. Mol Cancer Ther 16:1680–1692CrossRefGoogle Scholar
  23. 23.
    Zhong W, Oguljahan B, Xiao Y, Nelson J, Hernandez L, Garcia-Barrio M, Francis SC (2014) Serum and glucocorticoid-regulated kinase 1 promotes vascular smooth muscle cell proliferation via regulation of beta-catenin dynamics. Cell Signal 26:2765–2772CrossRefGoogle Scholar
  24. 24.
    Cheng Y, Cheung AK, Ko JM, Phoon YP, Chiu PM, Lo PH, Waterman ML, Lung ML (2013) Physiological beta-catenin signaling controls self-renewal networks and generation of stem-like cells from nasopharyngeal carcinoma. BMC Cell Biol 14:44CrossRefGoogle Scholar
  25. 25.
    Zhang K, Guo Y, Wang X, Zhao H, Ji Z, Cheng C, Li L, Fang Y, Xu D, Zhu HH, Gao WQ (2017) WNT/beta-catenin directs self-renewal symmetric cell division of hTERT(high) prostate cancer stem cells. Cancer Res 77:2534–2547CrossRefGoogle Scholar
  26. 26.
    Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W (1996) Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382:638–642CrossRefGoogle Scholar
  27. 27.
    Shang S, Hua F, Hu ZW (2017) The regulation of beta-catenin activity and function in cancer: therapeutic opportunities. Oncotarget 8:33972–33989Google Scholar
  28. 28.
    Minami Y, Oishi I, Endo M, Nishita M (2010) Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases. Dev Dyn 239:1–15Google Scholar
  29. 29.
    Green J, Nusse R, van Amerongen R (2014) The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction. Cold Spring Harb Perspect Biol 6.  https://doi.org/10.1101/cshperspect.a009175
  30. 30.
    Davies AH, Zoubeidi A (2016) The androgen receptor bridges stem cell-associated signaling nodes in prostate stem cells. Stem Cells Int 2016:4829602CrossRefGoogle Scholar
  31. 31.
    Tzortzis V, Samarinas M, Zachos I, Oeconomou A, Pisters LL, Bargiota A (2017) Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications. Hormones (Athens) 16:115–123Google Scholar
  32. 32.
    Taylor LG, Canfield SE, Du XL (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115:2388–2399CrossRefGoogle Scholar
  33. 33.
    Oakley RH, Cidlowski JA (2013) The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol 132:1033–1044CrossRefGoogle Scholar
  34. 34.
    Lin KT, Wang LH (2016) New dimension of glucocorticoids in cancer treatment. Steroids 111:84–88CrossRefGoogle Scholar
  35. 35.
    Gennari A, Salvadori B, Tognoni A, Conte PF (1996) Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. Ann Oncol 7:978–979CrossRefGoogle Scholar
  36. 36.
    Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S, Yonesaka K, Hayashi H, Makimura C, Okamoto K, Kiyota H, Tsurutani J, Miyazaki M, Yoshinaga M, Fujiwara K, Yamazoe Y, Moriyama K, Tsubaki M, Chiba Y, Nishida S, Nakagawa K (2011) High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol 16:244–249CrossRefGoogle Scholar
  37. 37.
    Kach J, Conzen SD, Szmulewitz RZ (2015) Targeting the glucocorticoid receptor in breast and prostate cancers. Sci Transl Med 7:305ps319CrossRefGoogle Scholar
  38. 38.
    Cadepond F, Ulmann A, Baulieu EE (1997) RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 48:129–156CrossRefGoogle Scholar
  39. 39.
    Tangir J, Bonafe N, Gilmore-Hebert M, Henegariu O, Chambers SK (2004) SGK1, a potential regulator of c-fms related breast cancer aggressiveness. Clin Exp Metastasis 21:477–483CrossRefGoogle Scholar
  40. 40.
    Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD (2004) Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 64:1757–1764CrossRefGoogle Scholar
  41. 41.
    Cheng J, Truong LD, Wu X, Kuhl D, Lang F, Du J (2010) Serum- and glucocorticoid-regulated kinase 1 is upregulated following unilateral ureteral obstruction causing epithelial-mesenchymal transition. Kidney Int 78:668–678CrossRefGoogle Scholar
  42. 42.
    Dehner M, Hadjihannas M, Weiske J, Huber O, Behrens J (2008) Wnt signaling inhibits Forkhead box O3a-induced transcription and apoptosis through up-regulation of serum- and glucocorticoid-inducible kinase 1. J Biol Chem 283:19201–19210CrossRefGoogle Scholar
  43. 43.
    Kriegl L, Horst D, Reiche JA, Engel J, Kirchner T, Jung A (2010) LEF-1 and TCF4 expression correlate inversely with survival in colorectal cancer. J Transl Med 8:123CrossRefGoogle Scholar
  44. 44.
    Eichhoff OM, Weeraratna A, Zipser MC, Denat L, Widmer DS, Xu M, Kriegl L, Kirchner T, Larue L, Dummer R, Hoek KS (2011) Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell Melanoma Res 24:631–642CrossRefGoogle Scholar
  45. 45.
    Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF 2nd, Zhang Z, Wu CC, Chen L, Wu R et al (2014) Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A 111:17266–17271CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Radiation OncologyUniversity of Rochester School of Medicine and DentistryRochesterUSA
  2. 2.Department of UrologyNingbo Urology and Nephrology HospitalNingboPeople’s Republic of China
  3. 3.Department of Radiation Oncology, James P. Wilmot Cancer CenterUniversity of RochesterRochesterUSA

Personalised recommendations